Gelteq Ltd Logo

Gelteq Ltd

Ingestible gel platform for enhanced oral delivery of drugs & nutrients for human & animal health.

GELS | US

Overview

Corporate Details

ISIN(s):
AU0000218109
LEI:
Country:
United States of America
Address:
LEVEL 4, 3205 SOUTH MELBOURNE VIC
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gelteq Ltd is a biotechnology company specializing in a proprietary, ingestible gel platform for the oral delivery of drugs and nutrients. Its patented technology converts existing orally delivered compounds into a customizable gel format designed to improve absorption, reduce choking risks, and address issues like dysphagia. A key feature of the platform is its stable matrix that can simultaneously integrate both water-soluble and lipid-soluble components. The company operates on a partnership model, providing white-label and tailored solutions for the pharmaceutical, nutraceutical, sports nutrition, and pet care industries, serving both human and animal markets. The technology was developed in collaboration with Monash University.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gelteq Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gelteq Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gelteq Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF

Talk to a Data Expert

Have a question? We'll get back to you promptly.